Candid Therapeutics Acquired by UCB | Healthcare M&A Deal

UCB has acquired Candid Therapeutics, a substance abuse treatment business in the United States. Candid Therapeutics develops immunology-focused therapies, including novel T-cell engagers, aimed at modulating immune responses for therapeutic benefit. UCB acquisitions in healthcare M&A are designed to extend its existing immunology pipeline by adding Candid Therapeutics capabilities in T-cell engager research. This strategic acquisition is structured as an add on acquisition, with deal size undisclosed and status announced, supporting UCB acquisitions and broader substance abuse treatment acquisition strategy.